Trinity Biotech PLC balance sheet TRIB

Annual Quarterly

As of Dec 31, 2024, Trinity Biotech PLC had total assets of $103.3 million and total liabilities of $138.5 million. Total assets were up 73.8% from a year earlier. Stockholders' equity was negative, at -$35.2 million, because liabilities exceed assets. It held $5.2 million in cash and investments against $210,000 of total debt, net cash of $5.0 million. The current ratio, current assets divided by current liabilities, was 1.28.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017
Assets
Cash	5 +40.0%	4 -43.9%	7 -74.6%	26 -5.2%	27 +79.4%	15 -49.7%	30 -47.4%	58
Cash and investments	5 +40.0%	4 -43.9%	7 -74.6%	26 -5.2%	27 +79.4%	15 -49.7%	30 -47.4%	58
Receivables	16 +15.6%	14 -11.8%	16 -2.3%	16 -28.9%	23 +8.0%	21 -14.1%	24 +17.8%	21
Inventory	19 -2.8%	20 -11.4%	23 -22.7%	29 -3.6%	30 -5.6%	32 +5.5%	30 -7.5%	33
Total current assets	41 +5.3%	39 -16.3%	47 -35.8%	73 -12.7%	83 +16.7%	71 -17.6%	87 -23.0%	113
Property and equipment, net	5 +144.2%	2 -66.7%	6 -4.0%	6 -30.8%	9 -8.0%	9 +73.3%	5 -7.6%	6
Total assets	103 +73.8%	59 -35.5%	92 -22.5%	119 -8.8%	130 -0.5%	131 -13.6%	152 -21.4%	193
Liabilities and equity
Accounts payable	7 +75.9%	4 -37.4%	6 -8.3%	7 -4.8%	7 -9.3%	8 -3.5%	8 +0.9%	8
Total current liabilities	32 +113.5%	15 -13.3%	17 -82.7%	100 +271.4%	27 +39.1%	19 +10.5%	18 -17.1%	21
Total liabilities	138 +66.1%	83 -11.6%	94 -20.9%	119 -10.1%	133 +5.0%	126 +17.4%	108 -15.8%	128
Stockholders' equity	-35 -46.9%	-24 -1000.6%	-2 -582.1%	-0 +85.6%	-2 -147.1%	5 -89.3%	44 -32.4%	65
Debt
Debt due within a year	—	—	—	—	—	—	19	—
Long-term debt	0 +0.0%	0 +0.0%	0 -99.7%	83 +0.8%	83 +0.8%	82 +0.8%	81 -12.5%	93
Total debt	0 +0.0%	0 +0.0%	0 -99.8%	83 +7895.4%	1 +0.0%	1 -98.7%	100 +9487.3%	1
Net cash	5 +42.4%	3 -45.3%	6 +108.6%	-57 -318.4%	26 +85.2%	14 +127.8%	-70 -223.1%	57
Ratios
Current ratio	1.28x	2.60x	2.69x	0.72x	3.08x	3.67x	4.92x	5.30x
Debt to equity	—	—	—	—	—	0.22x	2.27x	0.02x
Debt to EBITDA	—	—	0.01x	—	8.54x	—	—	—
Return on equity	—	—	—	—	—	-615.13%	-51.43%	-59.30%
Return on assets	-30.22%	-62.03%	-47.32%	-1.56%	-4.61%	-22.12%	-14.94%	-20.03%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as: TRIB (Nasdaq)
Fiscal year ends: December 31
Incorporated in: Ireland
Headquarters: Wicklow
SEC filer status: Non-accelerated filer
SEC CIK: 888721

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.